Benefit-risk evaluation of Fuzheng Yiliu Decoction combined with chemotherapy for treating non-small cell lung cancer using multicriteria decision analysis
These findings suggest that combining Fuzheng Yiliu Decoction with chemotherapy improves therapeutic efficacy and reduces chemotherapy's adverse side effects, offering a promising treatment strategy for NSCLC. This study provides valuable insights into enhancing treatment strategies and clinical decision-making in managing NSCLC.
Authors
- Yuanchao Zhang (ORCID: https://orcid.org/0000-0001-8191-4899)
- Jianjun Wu (ORCID: https://orcid.org/0000-0002-8044-3017)
- Jinbin Wang (ORCID: https://orcid.org/0000-0001-7080-4264)
- Di Ma (ORCID: https://orcid.org/0000-0002-7051-7393)
- Yingying Yang (ORCID: https://orcid.org/0000-0001-7458-1379)
- Keqin Gao (ORCID: https://orcid.org/0000-0002-0104-0544)
- Shenwen He
- Yan Di (ORCID: https://orcid.org/0000-0002-5271-0026)
Institutions
- Gansu University of Traditional Chinese Medicine (CN)
- Lanzhou University of Finance and Economics (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-09-23
- DOI
- https://doi.org/10.3389/fonc.2025.1627904
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Northwestern University
- National Natural Science Foundation of China